Arrowhead Pharmaceuticals (ARWR) revenue

Revenue · fiscal 2026
$450.82M

Arrowhead Pharmaceuticals (ARWR) reported revenue of $450.82M in fiscal 2026 (the year ended September 30, 2026). That is 45.6% lower than the $829.45M of fiscal 2025. Figures as of 18 Nov 2026, 09:06 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2026
$450.82M
Change on fiscal 2025
−45.6%
Growth, 5 years
+26.7% a year
Growth, 10 years
+121.5% a year
Highest on record
$829.45Mfiscal 2025
Lowest on record
$146.88Kfiscal 2012
Fiscal years on record
162011–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Arrowhead Pharmaceuticals revenue, in more detail

Over the five fiscal years to 2026 revenue grew at a compound 26.7% a year; over ten years the rate was 121.5% a year. Across the 16 fiscal years on record (2011–2026), the highest was $829.45M in fiscal 2025 and the lowest $146.88K in fiscal 2012.

History · 16 fiscal years

Revenue by fiscal year

Arrowhead Pharmaceuticals revenue, year by year

Arrowhead Pharmaceuticals (ARWR) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2026$450.82M 45.6% down
2025$829.45M 23,258.2% up
2024$3.55M 98.5% down
2023$240.74M 1.0% down
2022$243.23M 75.9% up
2021$138.29M 57.2% up
2020$87.99M 47.9% down
2019$168.80M 945.7% up
2018$16.14M 48.6% down
2017$31.41M 19,736.5% up
2016$158.33K 58.6% down
2015$382.00K 118.3% up
2014$175.00K 39.7% down
2013$290.27K 97.6% up
2012$146.88K 50.4% down
2011$296.14K—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Arrowhead Pharmaceuticals and comparable companies
CompanyRevenueFiscal year
Axsome Therapeutics AXSM$638.50M2025
Chemed CHE$2.53B2025
Arrowhead Pharmaceuticals ARWR$450.82M2026
MSA Safety MSA$1.87B2025
CG Oncology CGON$4.04M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ARWR

Arrowhead Pharmaceuticals, figure by figure

Arrowhead Pharmaceuticals (ARWR) overview: price, valuation and scorecardAll health care companies by market value

Arrowhead Pharmaceuticals revenue: questions and answers

What is Arrowhead Pharmaceuticals's revenue?

Arrowhead Pharmaceuticals (ARWR) reported revenue of $450.82M in fiscal 2026 (the year ended September 30, 2026). That is 45.6% lower than the $829.45M of fiscal 2025.

What is the growth rate of Arrowhead Pharmaceuticals's revenue?

Over the five fiscal years to 2026 revenue grew at a compound 26.7% a year; over ten years the rate was 121.5% a year.

What are the highest and lowest revenue figures on record for Arrowhead Pharmaceuticals?

Across the 16 fiscal years on record (2011–2026), the highest was $829.45M in fiscal 2025 and the lowest $146.88K in fiscal 2012.

How is Arrowhead Pharmaceuticals's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Arrowhead Pharmaceuticals it is on record here for 16 fiscal years, 2011 to 2026.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Arrowhead Pharmaceuticals (ARWR) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/ARWR/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.